MENU
+Compare
PHAT
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$9.63
Change
+$0.58 (+6.41%)
Capitalization
672.31M

PHAT Phathom Pharmaceuticals Forecast, Technical & Fundamental Analysis

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company... Show more

PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAT with price predictions
Jul 25, 2025

Momentum Indicator for PHAT turns positive, indicating new upward trend

PHAT saw its Momentum Indicator move above the 0 level on July 25, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned positive. In of the 82 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where PHAT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PHAT moved out of overbought territory on June 23, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for PHAT turned negative on June 26, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PHAT entered a downward trend on July 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (18.028). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). PHAT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (7.831) is also within normal values, averaging (278.844).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAT is expected to report earnings to fall 15.42% to -90 cents per share on August 07

Phathom Pharmaceuticals PHAT Stock Earnings Reports
Q2'25
Est.
$-0.90
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.42
Q3'24
Beat
by $0.15
Q2'24
Missed
by $0.24
The last earnings report on May 01 showed earnings per share of -107 cents, beating the estimate of -111 cents. With 1.67M shares outstanding, the current market capitalization sits at 672.31M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Campus Drive
Phone
+1 877 742-8466
Employees
452
Web
https://www.phathompharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OWLLX11.070.07
+0.64%
Channing Intrinsic Value Sm-Cp Instl
ETLNX15.650.10
+0.64%
Eventide Large Cap Focus N
NQVCX54.650.32
+0.59%
Nuveen Multi Cap Value C
GABIX49.810.16
+0.32%
Gabelli Asset I
HFQAX7.01-0.03
-0.43%
Janus Henderson Global Equity Income A

PHAT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with RGNX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+6.41%
RGNX - PHAT
36%
Loosely correlated
-1.86%
ACIU - PHAT
36%
Loosely correlated
N/A
URGN - PHAT
35%
Loosely correlated
+5.28%
PDSB - PHAT
34%
Loosely correlated
-2.48%
SYRE - PHAT
33%
Poorly correlated
+1.08%
More